Dozens of foreign CEOs, including leaders from FedEx, Siemens, BMW, and Mercedes-Benz, will attend the China Development ...

"By identifying genes that show evidence of human disease causality, the combined framework has the potential to prioritise drug candidates with increased likelihood of approval," said Illumina ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Chinese authorities met with Walmart executives following reports of the retailer asking Chinese suppliers to absorb higher ...

A sneak peek at upcoming San Diego community events, including street fairs, festivals, concerts, performances, art shows and ...

Genmab A/S announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FR?)-targeted, TOPO1 antibody-drug ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

San Diego, CA.-based Illumina Inc. provides sequencing and array-based solutions for genetic and genomic analysis across a wide range of markets, driving their adoption in research and clinical ...

In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other stocks that Jim Cramer discusses in latest lightning round. On Thursday, Jim Cramer ...

The stock's rise snapped a four-day losing streak.

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.